Furthermore, compared with patients with type 2 diabetes, those with DN are on a fast-track to progress to a cardiovascular event, including premature cardiovascular death.1 3 The identification of individuals at high risk of cardiovascular deaths in the short term could help clinicians to prioritize new therapy (such as Sodium Glucose Co-Transporter-2 (SGLT-2) inhibitors) to delay a fatal (or non-fatal) cardiovascular event. The gene discussed is SLC5A2; the disease is liver dysplastic nodule.